Fatal Anaphylaxis: Mortality Rate and Risk Factors

Paul J Turner, Elina Jerschow, Thisanayagam Umasunthar, Robert Lin, Dianne E Campbell, Robert J Boyle, Paul J Turner, Elina Jerschow, Thisanayagam Umasunthar, Robert Lin, Dianne E Campbell, Robert J Boyle

Abstract

Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis.

Keywords: Anaphylaxis; Drug allergy; Food allergy; Insect sting; Mortality.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Estimated rates of fatal drug, food, and venom anaphylaxis compared with other risks for the general population. Reference risks are for the US population, unless otherwise stated. Bars represent the range of estimates from recent population-based studies of fatal anaphylaxis.
Figure 2
Figure 2
Estimated rates of fatal food and venom anaphylaxis for people with known food allergy or insect venom allergy. Reference risks are for the US population, unless otherwise stated. Data shown for individuals with food allergy are the 95% confidence interval of fatal food anaphylaxis risk, derived from the systematic review of Umasunthar et al. Data shown for individuals with insect venom allergy were calculated using the range of estimates from recent population-based studies of fatal venom anaphylaxis, and an estimated 3% population prevalence of insect venom allergy.

References

    1. Wood R.A., Camargo C.A., Jr., Lieberman P., Sampson H.A., Schwartz L.B., Zitt M. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:461–467.
    1. Ma L., Danoff T.M., Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075–1083.
    1. Rona R.J., Keil T., Summers C., Gislason D., Zuidmeer L., Sodergren E. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120:638–646.
    1. Branum A.M., Lukacs S.L. Food allergy among children in the United States. Pediatrics. 2009;124:1549–1555.
    1. Tanno L.K., Ganem F., Demoly P., Toscano C.M., Bierrenbach A.L. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy. 2012;67:783–789.
    1. Jerschow E., Lin R.Y., Scaperotti M.M., McGinn A.P. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134:1318–1328.e1317.
    1. Liew W.K., Williamson E., Tang M.L. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123:434–442.
    1. Low I., Stables S. Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology. 2006;38:328–332.
    1. Poulos L.M., Waters A.M., Correll P.K., Loblay R.H., Marks G.B. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol. 2007;120:878–884.
    1. Pumphrey R.S. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30:1144–1150.
    1. Mullins R.J., Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46:1099–1110.
    1. Xu Y.S., Kastner M., Harada L., Xu A., Salter J., Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy Asthma Clin Immunol. 2014;10:38.
    1. Reitter M., Petitpain N., Latarche C., Cottin J., Massy N., Demoly P. Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy. 2014;69:954–959.
    1. Turner P.J., Gowland M.H., Sharma V., Ierodiakonou D., Harper N., Garcez T. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135:956–963.
    1. Tanno L.K., Simons F.E.R., Annesi-Maesano I., Calderon M.A., Aymé S., Demoly P. Fatal anaphylaxis registries data support changes in the WHO anaphylaxis mortality coding rules. Orphanet J Rare Dis. 2017;12:8.
    1. Grabenhenrich L.B., Dölle S., Moneret-Vautrin A., Köhli A., Lange L., Spindler T. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137:1128–1137.e1.
    1. Worm M., Moneret-Vautrin A., Scherer K., Lang R., Fernandez-Rivas M., Cardona V. First European data from the network of severe allergic reactions (NORA) Allergy. 2014;69:1397–1404.
    1. Turner P.J., Campbell D.E. Epidemiology of severe anaphylaxis: can we use population-based data to understand anaphylaxis? Curr Opin Allergy Clin Immunol. 2016;16:441–450.
    1. Lin R.Y., Anderson A.S., Shah S.N., Nurruzzaman F. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990-2006. Ann Allergy Asthma Immunol. 2008;101:387–393.
    1. Jeppesen A.N., Christiansen C.F., Froslev T., Sorensen H.T. Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012. J Allergy Clin Immunol. 2016;137:1143–1147.
    1. Ring J., Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1:466–469.
    1. Li Z.D., Liu W.G., Zhao Z.Q., Shen Y.W., Chen Y.J. Analysis of 59 anaphylactic death cases. Fa Yi Xue Za Zhi. 2015;31:206–210.
    1. Shen Y., Li L., Grant J., Rubio A., Zhao Z., Zhang X. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int. 2009;186:1–5.
    1. Yilmaz R., Yuksekbas O., Erkol Z., Bulut E.R., Arslan M.N. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol. 2009;30:346–349.
    1. Gurrieri C., Weingarten T.N., Martin D.P., Babovic N., Narr B.J., Sprung J. Allergic reactions during anesthesia at a large United States referral center. Anesth Analg. 2011;113:1202–1212.
    1. Hitti E.A., Zaitoun F., Harmouche E., Saliba M., Mufarrij A. Acute allergic reactions in the emergency department: characteristics and management practices. Eur J Emerg Med. 2015;22:253–259.
    1. Jares E.J., Baena-Cagnani C.E., Sánchez-Borges M., Ensina L.F., Arias-Cruz A., Gómez M. Drug-induced anaphylaxis in Latin American Countries. J Allergy Clin Immunol Pract. 2015;3:780–788.
    1. Kuhlen J.L., Jr., Camargo C.A., Jr., Balekian D.S., Blumenthal K.G., Guyer A., Morris T. Antibiotics are the most commonly identified cause of perioperative hypersensitivity reactions. J Allergy Clin Immunol Pract. 2016;4:697–704.
    1. Renaudin J.M., Beaudouin E., Ponvert C., Demoly P., Moneret-Vautrin D.A. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy. 2013;68:929–937.
    1. Saff R.R., Camargo C.A., Jr., Clark S., Rudders S.A., Long A.A., Banerji A. Utility of ICD-9-CM codes for identification of allergic drug reactions. J Allergy Clin Immunol Pract. 2016;4:114–119.e111.
    1. Smit D.V., Cameron P.A., Rainer T.H. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. J Emerg Med. 2005;28:381–388.
    1. Tang R., Xu H.-Y., Cao J., Chen S., Sun J.-L., Hu H. Clinical characteristics of inpatients with anaphylaxis in China. Biomed Res Int. 2015;2015:429534.
    1. Worm M., Eckermann O., Dölle S., Aberer W., Beyer K., Hawranek T. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int. 2014;111:367–375.
    1. Yang M.S., Lee S.H., Kim T.W., Kwon J.W., Lee S.M., Kim S.H. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008;100:31–36.
    1. Ye Y.M., Kim M.K., Kang H.R., Kim T.B., Sohn S.W., Koh Y.I. Predictors of the severity and serious outcomes of anaphylaxis in Korean adults: a multicenter retrospective case study. Ann Allergy Asthma Immunol Res. 2015;7:22–29.
    1. Scheinfeld M.H., Sprayregen S., Jerschow E., Dym R.J. Contrast is the new penicillin, and possibly worse. J Am Coll Radiol. 2015;12:942–943.
    1. Florvaag E., Johansson S.G. The pholcodine story. Immunol Allergy Clin North Am. 2009;29:419–427.
    1. Florvaag E., Johansson S.G. Pholcodine in cough medicines and IgE-sensitization in the EU: an urgent task. Allergy. 2012;67:581–582.
    1. Florvaag E., Johansson S.G., Irgens A., de Pater G.H. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy. 2011;66:955–960.
    1. Johansson S.G., Florvaag E., Oman H., Poulsen L.K., Mertes P.M., Harper N.J. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy. 2010;65:498–502.
    1. Johansson S.G., Oman H., Nopp A., Florvaag E. Pholcodine caused anaphylaxis in Sweden 30 years ago. Allergy. 2009;64:820–821.
    1. Greenberger P.A. Fatal and near-fatal anaphylaxis: factors that can worsen or contribute to fatal outcomes. Immunol Allergy Clin North Am. 2015;35:375–386.
    1. Lee S., Hess E.P., Nestler D.M., Bellamkonda Athmaram V.R., Bellolio M.F., Decker W.W. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. 2013;131:1103–1108.
    1. Nassiri M., Babina M., Dolle S., Edenharter G., Rueff F., Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol. 2015;135:491–499.
    1. Corre K.A., Spielberg T.E. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point. Ann Emerg Med. 1988;17:145–149.
    1. Umasunthar T., Leonardi-Bee J., Hodes M., Turner P.J., Gore C., Habibi P. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2013;43:1333–1341.
    1. Umasunthar T., Leonardi-Bee J., Turner P.J., Hodes M., Gore C., Warner J.O. Incidence of food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1621–1636.
    1. Golden D.B. Anaphylaxis to insect stings. Immunol Allergy Clin North Am. 2015;35:287–302.
    1. Hu W., Grbich C., Kemp A. When doctors disagree: a qualitative study of doctors' and parents' views on the risks of childhood food allergy. Health Expect. 2008;11:208–219.
    1. Osborne N.J., Koplin J.J., Martin P.E., Gurrin L.C., Lowe A.J., Matheson M.C. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol. 2011;127:668–676.e1-2.
    1. Perkin M.R., Logan K., Tseng A., Raji B., Ayis S., Peacock J. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med. 2016;374:1733–1743.
    1. Sampson H.A., Mendelson L., Rosen J.P. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380–384.
    1. Bock S.A., Muñoz-Furlong A., Sampson H.A. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119:1016–1018.
    1. Pumphrey R.S., Gowland M.H. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol. 2007;119:1018–1019.
    1. Turner P.J., DunnGalvin A., Hourihane J.O. The emperor has no symptoms: the risks of a blanket approach to using epinephrine autoinjectors for all allergic reactions. J Allergy Clin Immunol Pract. 2016;4:1143–1146.
    1. Sheikh A., Shehata Y.A., Brown S.G., Simons F.E. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy. 2009;64:204–212.
    1. Brown S.G. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas. 2006;18:155–169.
    1. Smith P.L., Kagey-Sobotka A., Bleecker E.R., Traystman R., Kaplan A.P., Gralnick H. Physiologic manifestations of human anaphylaxis. J Clin Invest. 1980;66:1072–1080.
    1. Pumphrey R., Sturm G. Risk factors for fatal anaphylaxis. In: Moneret-Vautrin D.A., editor. Advances in Anaphylaxis Management. Future Medicine; London: 2014. pp. 32–48.
    1. Turner P.J., Baumert J.L., Beyer K., Boyle R.J., Chan C.H., Clark A.T. Can we identify patients at risk of life-threatening allergic reactions to food? Allergy. 2016;71:1241–1255.
    1. Mehr S., Turner P.J., Joshi P., Wong M., Campbell D.E. Safety and clinical predictors of reacting to extensively heated cow's milk challenge in cow's milk-allergic children. Ann Allergy Asthma Immunol. 2014;113:425–429.
    1. Turner P.J., Mehr S., Joshi P., Tan J., Wong M., Kakakios A. Safety of food challenges to extensively heated egg in egg-allergic children: a prospective cohort study. Pediatric Allergy Immunol. 2013;24:450–455.
    1. Vadas P., Gold M., Perelman B., Liss G.M., Lack G., Blyth T. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358:28–35.
    1. Motosue M.S., Bellolio M.F., Van Houten H.K., Shah N.D., Campbell R.L. Increasing emergency department visits for anaphylaxis, 2005-2014. J Allergy Clin Immunol Pract. 2017;5:171–175.e3.
    1. Manuyakorn W., Benjaponpitak S., Kamchaisatian W., Vilaiyuk S., Sasisakulporn C., Jotikasthira W. Pediatric anaphylaxis: triggers, clinical features, and treatment in a tertiary-care hospital. Asian Pac J Allergy Immunol. 2015;33:281–288.
    1. Graft D.F. Insect sting allergy. Med Clin North Am. 2006;90:211–232.
    1. Lieberman P., Simons F.E. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. Clin Exp Allergy. 2015;45:1288–1295.
    1. Alvarez-Twose I., Zanotti R., Gonzalez-de-Olano D., Bonadonna P., Vega A., Matito A. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133:520–528.
    1. Zanotti R., Lombardo C., Passalacqua G., Caimmi C., Bonifacio M., De Matteis D. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136:135–139.
    1. Vos B.J.P.R., van Anrooij B., van Doormaal J.J., Dubois A.E.J., Oude-Elberink J.N.G. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at risk patients. J Allergy Clin Immunol Pract. 2017;5:1264–1271.
    1. Pravettoni V., Piantanida M., Primavesi L., Forti S., Pastorello E.A. Basal platelet-activating factor acetylhydrolase: prognostic marker of severe Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2014;133:1218–1220.
    1. Boyle R.J., Dickson R., Hockenhull J., Cherry M.G., Elremeli M. Immunotherapy for hymenoptera venom allergy: too expensive for European health care? Allergy. 2013;68:1341–1342.
    1. Boyle R.J., Elremeli M., Hockenhull J., Cherry M.G., Bulsara M.K., Daniels M. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838.
    1. Hockenhull J., Elremeli M., Cherry M.G., Mahon J., Lai M., Darroch J. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy. Health Technol Assess. 2012;16 III-IV,1-110.
    1. Oude Elberink J.N., De Monchy J.G., Van Der Heide S., Guyatt G.H., Dubois A.E. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol. 2002;110:174–182.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj